EcoR1 Capital, LLC bought $40.0M of Aktis Oncology (AKTS)
Executed Jan 12, disclosed Jan 13, the same day.
Over the 21 trading sessions from the disclosed entry session (Jan 12), the stock returned -20.7% (delay-adjusted); from the execution session (Jan 12), -20.7%. Derived: entry at the session's open, exit at the close 20 sessions later.
EcoR1 Capital, LLC (Director) filed 2 Form 4 reports as a reporting entity in the trailing twelve months (2 purchases, 0 sales), most often in ZYME. Across 2 priced purchase filings, the average 21-session return was +2.8% from execution and -5.0% from disclosure (delay-adjusted; derived). The largest single filing was $40.0M of AKTS (2,222,222 sh across 2 lots, as filed), executed Jan 12.
Healthcare · Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharm…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→